At Plus Therapeutics, our mission is to radically improve outcomes for patients with central nervous system (CNS) cancers through innovative, targeted radiotherapeutics.
In a recent Xtalks Clinical Edge™ feature, our President and CEO, Dr. Marc Hedrick, sat down with Soumya Shashikumar to discuss how we’re tackling some of neuro-oncology’s toughest challenges—including glioblastoma (GBM) and leptomeningeal metastases (LM)—through intrathecal and catheter-based delivery of novel radiopharmaceuticals like REYOBIQ™ (rhenium Re186 obisbemeda).
“From intrathecal injections to patient-centric clinical trial design, we’re rethinking how precision medicine can be delivered directly to where it’s needed most—in the brain and spine,” said Dr. Hedrick.
Read the full interview here:
Xtalks Clinical Edge Feature on Plus Therapeutics
Explore Our Active Clinical Trials
If you or someone you know may be eligible, reach out to us at respect@plustherapeutics.com or visit the trial pages to learn more.
#CNSCancers #Glioblastoma #LeptomeningealDisease #NeuroOncology #Radiotherapeutics #Radiopharmaceuticals #PrecisionMedicine #TargetedTherapy #IntrathecalDelivery #CED #ClinicalTrials #PSTV
Recent Comments